Approval · Notice of Compliance 10120 · 2009
AVANDARYL: Notice of Compliance 10120
Issued March 25, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10120
- Date
- March 25, 2009
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the Contraindications, Warnings & Precautions, Adverse Reactions, Drug Interactions, Overdosage, Clinical Trials, and Part III: Consumer Information sections of the product monograph
- Therapeutic class
- Antidiabetic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVANDARYL | Not yet assigned | — |
Medicinal ingredients
- ROSIGLITAZONE MALEATE 4 MG per TAB
- GLIMEPIRIDE 1 MG per TAB
- GLIMEPIRIDE 2 MG per TAB
- GLIMEPIRIDE 4 MG per TAB